Calidi Biotherapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
FY EPS (est.)
-$5.68next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 13 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Cash and Cash Equivalents Quarterly6.8MTarget: Sufficient capital to fund Phase 1 clinical trials
Research and Development (R&D) Expenses Quarterly2.6MTarget: IND-enabling studies and manufacturing scale-up
Watch Items
- IND Submission for CLD-401Trigger: FDA acceptance of IND applicationAction: Initiate Phase 1 clinical trial in early 2027
- Going Concern StatusTrigger: Cash runway falling below 12 monthsAction: Secure additional equity financing, partnerships, or non-dilutive funding
Research as of 20 Jun 2026